title: Sirolimus-eluting stent for the treatment of in-stent restenosis: a quantitative coronary angiography and three-dimensional intravascular ultrasound study.
abstract: BACKGROUND
  We have previously reported the safety and effectiveness of sirolimus-eluting stents for the treatment of de novo coronary lesions. The present investigation explored the potential of this technology to treat in-stent restenosis.
  
  
  RESULTS
  Twenty-five patients with in-stent restenosis were successfully treated with the implantation of 1 or 2 sirolimus-eluting Bx VELOCITY stents in São Paulo, Brazil. Nine patients received 2 stents (1.4 stents per lesion). Angiographic and volumetric intravascular ultrasound (IVUS) images were obtained after the procedure and at 4 and 12 months. All vessels were patent at the time of 12-month angiography. Angiographic late loss averaged 0.07+/-0.2 mm in-stent and -0.05+/-0.3 mm in-lesion at 4 months, and 0.36+/-0.46 mm in-stent and 0.16+/-0.42 mm in-lesion after 12 months. No patient had in-stent or stent margin restenosis at 4 months, and only one patient developed in-stent restenosis at 1-year follow-up. Intimal hyperplasia by 3-dimensional IVUS was 0.92+/-1.9 mm(3) at 4 months and 2.55+/-4.9 mm(3) after 1 year. Percent volume obstruction was 0.81+/-1.7% and 1.76+/-3.4% at the 4- and 12-month follow-up, respectively. There was no evidence of stent malapposition either acutely or in the follow-up IVUS images, and there were no deaths, stent thromboses, or repeat revascularizations.
  
  
  CONCLUSIONS
  This study demonstrates the safety and the potential utility of sirolimus-eluting Bx VELOCITY stents for the treatment of in-stent restenosis.
authors.affiliation: Institute Dante Pazzanese of Cardiology, São Paulo, Brazil. jesousa@uol.com.br
authors.forename: J Eduardo
authors.initials: JE
authors.lastname: Sousa
authors.forename: Marco A
authors.initials: MA
authors.lastname: Costa
authors.forename: Alexandre
authors.initials: A
authors.lastname: Abizaid
authors.forename: Amanda G M R
authors.initials: AG
authors.lastname: Sousa
authors.forename: Fausto
authors.initials: F
authors.lastname: Feres
authors.forename: Luiz A
authors.initials: LA
authors.lastname: Mattos
authors.forename: Marinella
authors.initials: M
authors.lastname: Centemero
authors.forename: Galo
authors.initials: G
authors.lastname: Maldonado
authors.forename: Andrea S
authors.initials: AS
authors.lastname: Abizaid
authors.forename: Ibraim
authors.initials: I
authors.lastname: Pinto
authors.forename: Robert
authors.initials: R
authors.lastname: Falotico
authors.forename: Judith
authors.initials: J
authors.lastname: Jaeger
authors.forename: Jeffrey J
authors.initials: JJ
authors.lastname: Popma
authors.forename: Patrick W
authors.initials: PW
authors.lastname: Serruys
mesh_terms: D003131:Combined Modality Therapy; D017023:Coronary Angiography; D023903:Coronary Restenosis / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000601:surgery; D003692:Delayed-Action Preparations; D019560:Echocardiography, Three-Dimensional; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D055502:Secondary Prevention; D020123:Sirolimus / Q000008:administration & dosage* / Q000627:therapeutic use; D015607:Stents / Q000009:adverse effects
chemical_list: D003692:Delayed-Action Preparations; D020123:Sirolimus